Recent Finacing
Recent Raise
FIT Biotech develops and licenses GTU® gene-transport vectors for DNA vaccines/gene therapy targeting cancer, infectious diseases (HIV, tuberculosis) and animal vaccines; FIT‑06 in phase‑2, GTU patents.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor